(Q33544594)

27 July 2017

title

Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis (English)

1 reference

27 July 2017

0 references

1 reference

Goldenberg MM

1

1 reference

27 July 2017

publication date

1 January 1999

1 reference

27 July 2017

published in

Clinical Therapeutics

1 reference

27 July 2017

volume

21

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

75-87; discussion 1-2

1 reference

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Cytokines in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Isolation and characterization of a tumor necrosis factor binding protein from urine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

High concentrations of soluble tumor necrosis factor receptors in ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Plasma tumor necrosis factor soluble receptors in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Interleukin-2-induced lymphocyte infiltration of multiple organs is differentially suppressed by soluble tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Unraveling function in the TNF ligand and receptor families

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988269-7

7 January 2021

10.1016/S0149-2918(00)88269-7

Identifiers

DOI

1 reference

27 July 2017

1 reference